Is levobuterol more tolerable than albuterol in adults with asthma or COPD?

Levalbuterol is NOT more tolerable than albuterol

Based on the highest quality evidence, levalbuterol offers no clinically meaningful advantage over albuterol in terms of tolerability for adults with asthma or COPD. The National Asthma Education and Prevention Program (NAEPP) guidelines explicitly state that levalbuterol administered at half the milligram dose of albuterol provides "comparable efficacy and safety" 1, 2.

Key Evidence from Guidelines

The NAEPP Expert Panel Report 3 (EPR-3) guidelines clearly position levalbuterol and albuterol as therapeutically equivalent when dosed appropriately:

• Levalbuterol 0.63 mg is equivalent to albuterol 1.25 mg for both efficacy and side effects 3
• Both medications are listed as acceptable short-acting beta-agonist (SABA) options without preference for one over the other 1
• The guidelines make no recommendation to use levalbuterol preferentially for patients experiencing side effects from albuterol

Research Evidence on Tolerability

The most rigorous systematic review and meta-analysis directly addressing this question found:

A 2013 systematic review of 7 randomized controlled trials (1,625 participants) demonstrated no significant differences in side effects between levalbuterol and albuterol 4. The authors concluded that "levalbuterol was not superior to albuterol regarding efficacy and safety" and recommended against using levalbuterol over albuterol for acute asthma.

Clinical Trial Data

A large 2008 multicenter randomized trial (479 hospitalized patients) comparing levalbuterol every 6-8 hours versus racemic albuterol every 1-4 hours found:

• Beta-mediated adverse effects were actually significantly GREATER with levalbuterol versus racemic albuterol (P < 0.001) 5
• This contradicts the theoretical advantage of levalbuterol

FDA Drug Label Information

The FDA-approved levalbuterol label acknowledges that adverse events are comparable to albuterol, listing similar beta-adrenergic side effects including:

• Tachycardia, tremor, nervousness
• Cardiovascular effects (arrhythmias, hypertension)
• Central nervous system stimulation 6

The Theoretical Rationale Does Not Translate Clinically

While levalbuterol is the isolated R-enantiomer of albuterol (removing the supposedly "inert" S-enantiomer), this pharmacologic distinction has not produced clinically meaningful improvements in tolerability:

• In stable COPD patients, a 2003 randomized trial found no significant differences in hand tremor, pulse rate, or oxygen saturation between levalbuterol and albuterol 7
• The theoretical benefits of removing S-albuterol have not materialized in real-world clinical outcomes

Cost Considerations

Multiple studies demonstrate that levalbuterol is significantly more expensive without providing additional clinical benefit:

• A 2015 study found mean total treatment costs were significantly greater with levalbuterol ($8,003) versus albuterol ($5,772; p = 0.006) with similar clinical outcomes 8
• Hospital length of stay was actually longer with levalbuterol (8.5 vs 6.8 days; p = 0.040) 8

Clinical Recommendation Algorithm

For adults with asthma or COPD requiring SABA therapy:

1. Start with albuterol as first-line SABA therapy
2. If patient experiences intolerable side effects (tremor, tachycardia, palpitations):
   • First, verify proper inhaler technique
   • Consider reducing albuterol dose or frequency
   • Optimize controller therapy to reduce SABA need
3. Do NOT switch to levalbuterol expecting improved tolerability—evidence does not support this
4. If beta-agonist side effects remain problematic despite optimization:
   • Consider adding ipratropium bromide (anticholinergic) for severe exacerbations 1
   • Intensify anti-inflammatory controller therapy to reduce rescue medication need

Common Pitfalls to Avoid

• Do not assume levalbuterol is "cleaner" or better tolerated based on its single-isomer formulation—clinical evidence does not support this
• Do not use levalbuterol as a solution for patients with beta-agonist side effects—address the underlying issue (excessive SABA use indicating poor asthma control)
• Do not justify levalbuterol use based on cost-effectiveness—it is consistently more expensive without clinical benefit 9, 8

The bottom line: Use albuterol as your standard SABA. Levalbuterol offers no tolerability advantage and costs significantly more.